The once-daily oral GLP-1 RA orforglipron produces clinically and statistically significant weight loss and cardiometabolic ...

The rollout of antiretroviral therapy for HIV showed how global solidarity and smart policy can overcome barriers to new treatments, say Jirair Ratevosian and Jeffrey L Sturchio The arrival of ...

Beyond GLP-1 RA prescriptions, chronic kidney disease (CKD) patients require comprehensive care from doctors, dietitians, & ...

Patients with heart failure using glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have less carbon dioxide equivalent (CO2e) greenhouse gas (GHG) emissions per patient per year.

Semaglutide is linked to significant weight loss and glucose levels in adults with schizophrenia, overweight/obesity, and ...

GLP-1 receptor agonists like Ozempic can be a lifeline for people with diabetes - helping stabilize blood glucose and lose ...

Compared with usual care, GLP-1 receptor agonists tirzepatide and semaglutide may be cost-effective options for patients with ...

Psoriasis patients treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) face a 78% lower risk of death and a 44% ...

GLP-1 receptor agonists may reduce the likelihood of mortality and increase odds for transplant wait-listing for patients ...

GLP-1 receptor agonist drugs protect against diabetic retinopathy, a common complication of diabetes that can lead to sight ...